Cortexyme Company

Cortexyme is developing treatments for Alzheimer's and other degenerative disorders.


Investors

Funding Status: IPO
Industry: Biotechnology, Health Care, Medical, Pharmaceutical
Estimated Revenue: $10M to $50M
Technology: Gene therapy
Number Of Exists: N/A
Headquarters: South San Francisco, California, United States
Total Funding: 225000000
Last Funding Date: 2019
Last Funding Type: Post-IPO Equity
Investor Type: N/A
Employee Number: 11-50
Investors Number: 13
Investment Stage: N/A
Founded Date: 2012